| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 05/18/2006 | US20060104964 Recombinant sequence, its preparation and use |
| 05/18/2006 | US20060104961 Mechanisms of myoblast transfer in treating heart failure |
| 05/18/2006 | US20060104960 Pharmaceuticals containing retinal stem cells |
| 05/18/2006 | US20060104956 gene expression inhibition; hairpin nucleic acids; for treatment of viral infections, tumors, and cancer |
| 05/18/2006 | US20060104948 Interferon immunotherapy |
| 05/18/2006 | US20060104947 Remedy for pemphigoid |
| 05/18/2006 | US20060104946 Method for treating inflammatory bowel disease |
| 05/18/2006 | US20060104945 Enhancement of B cell proliferation by IL-15 |
| 05/18/2006 | US20060104944 Activators and inhibitors of protease activated receptor2 (PAR2) and methods of use |
| 05/18/2006 | US20060104943 Vaccine comprising il-13 and an adjuvant |
| 05/18/2006 | US20060104942 Anticholesterol agents; anticholesterol agents; cardiovascular disorders; mixture of colony stimulating factor and hepatocyte growth factor |
| 05/18/2006 | US20060104913 Inhalable formulations for treating pulmonary hypertension and methods of using same |
| 05/18/2006 | US20060104897 Method for diagnosing and treating nis-expressing carcinomas and metastases |
| 05/18/2006 | DE3830494B4 Wasserlösliche Monoester als Solubilisatoren für pharmakologische Wirkstoffe und pharmazeutische Hilfsstoffe Water-soluble mono esters as solubilizers for pharmacologically active substances and pharmaceutical excipients |
| 05/18/2006 | DE102004055316A1 Verhinderung vertikaler Endoparasiten-Infektionen Prevention of vertical internal parasite infections |
| 05/18/2006 | CA2629751A1 Antimicrobial peptides |
| 05/18/2006 | CA2591474A1 Therapeutic or preventive agents for ischemic heart disease or ischemic cardiomyopathy |
| 05/18/2006 | CA2588087A1 Methods of reducing body fat |
| 05/18/2006 | CA2587469A1 Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis |
| 05/18/2006 | CA2587369A1 Mutant interferon .alpha. proteins and use thereof |
| 05/18/2006 | CA2587336A1 Ptpase inhibitors and t-cell activators for treating cancer |
| 05/18/2006 | CA2587188A1 Pharmaceutical preparation for the treatment of friedreich's ataxia |
| 05/18/2006 | CA2587018A1 Tweak as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death |
| 05/18/2006 | CA2586968A1 Medical device for delivering biologically active material |
| 05/18/2006 | CA2586936A1 Use of antioxidants for gene modulation |
| 05/18/2006 | CA2586915A1 Molecules which promote hematopoiesis |
| 05/18/2006 | CA2586811A1 Peptides derived from maurocalcine used as vectors for intracellular addressing of molecules of interest |
| 05/18/2006 | CA2586781A1 Treatment of an intestinal adenoma and/or adenocarcinoma by inhibition of notch pathway activation |
| 05/18/2006 | CA2586771A1 Stable formulations of insulinoptropic peptides |
| 05/18/2006 | CA2586688A1 Synergistic effects of combined administration of mirtazapine and a stimulant compound |
| 05/18/2006 | CA2586344A1 G protein coupled receptor agonists and antagonists and methods of use |
| 05/18/2006 | CA2586285A1 Antibody induced cell membrane wounding |
| 05/18/2006 | CA2586007A1 Composition and method for increasing apoptosis in cancer cells |
| 05/18/2006 | CA2585927A1 Polypeptides that bind baff and/or april |
| 05/18/2006 | CA2585446A1 Improved dosing regimen of temozolomide for treating cancer based on the patient's mgmt level |
| 05/18/2006 | CA2585442A1 Protein hydrolysate with antidiabetic effect |
| 05/18/2006 | CA2585056A1 Use of survivin to treat kidney failure |
| 05/18/2006 | CA2584806A1 Treatment of obesity and related disorders |
| 05/18/2006 | CA2584805A1 Peptide anti-tumor agent |
| 05/18/2006 | CA2584396A1 Modulators of retinol-retinol binding protein (rbp)-transthyretin (ttr) complex formation |
| 05/18/2006 | CA2584221A1 Adrenocorticotropic hormone analogs and related methods |
| 05/18/2006 | CA2583231A1 Compositions and methods for treatment of protein misfolding and protein aggregation diseases |
| 05/18/2006 | CA2579131A1 Method for purifying fsh |
| 05/18/2006 | CA2578176A1 Ophthalmic emulsions containing an immunosuppressive agent |
| 05/17/2006 | EP1657304A1 Blood-viscosity reducing agent |
| 05/17/2006 | EP1657256A2 Compositions and methods for the treatment of tumor |
| 05/17/2006 | EP1657255A1 Novel protein and method for producing the protein |
| 05/17/2006 | EP1657252A2 PGC-1, a novel brown fat PPAR gamma coactivator |
| 05/17/2006 | EP1657249A1 Antibiotic drosocin derivatives |
| 05/17/2006 | EP1656954A1 Therapeutic human albumin solutions with low prekallicrein activator (PKA) activity and process for obtaining them |
| 05/17/2006 | EP1656952A2 Polymer conjugates of interferon beta-1A and uses thereof |
| 05/17/2006 | EP1656949A1 Use of alpha-1 antitrypsin for the preparation of medicaments for the treatment of fibromyalgia |
| 05/17/2006 | EP1656948A1 Osteogenesis promoter |
| 05/17/2006 | EP1656947A1 Preventive and/or remedy for hematopoietic tumor |
| 05/17/2006 | EP1656946A1 Tissue adhesive using synthetic crosslinking |
| 05/17/2006 | EP1656945A1 Pharmaceutical composition comprising oligoarginine |
| 05/17/2006 | EP1656560A2 Diagnostic markers and pharmacological targets in heart failure and related reagents and methods of use thereof |
| 05/17/2006 | EP1656555A1 Methods and compositions for measuring biologically active natriuretic peptides and for improving their therapeutic potential |
| 05/17/2006 | EP1656458A2 Human autism susceptibility gene and uses thereof |
| 05/17/2006 | EP1656390A2 Compositions of lipopeptide antibiotic derivatives and methods of use thereof |
| 05/17/2006 | EP1656368A2 Substituted hertocyclic derivatives useful as antidiabetic and antiobesity agents and method |
| 05/17/2006 | EP1656158A2 Liquid, aqueous pharmaceutical composition of factor vii polypeptides |
| 05/17/2006 | EP1656156A2 Mobilization of hematopoietic cells |
| 05/17/2006 | EP1656155A2 Use of genes differentially expressed during aging of liver for treatment and diagnosis |
| 05/17/2006 | EP1656081A2 Acellular matrix implants for treatment of articular cartilage, bone or osteochondral defects and injuries and a method for use thereof |
| 05/17/2006 | EP1413174A4 Mounting arrangement for auxiliary burner or lance |
| 05/17/2006 | EP1387660A4 Use of 3-position cyclosporin derivatives for hair growth |
| 05/17/2006 | EP1330293B1 Controlled release composition comprising lactic acid polymer, and method of producing the same |
| 05/17/2006 | EP1325126B1 Human ion-exchanger proteins and polynucleotides encoding the same |
| 05/17/2006 | EP1296711B1 Hpv-e7 for human papilloma virus treatment |
| 05/17/2006 | EP1272220B1 Formulation for the prevention of cardiovascular disease |
| 05/17/2006 | EP1231983B1 Combination of dhea and calcitonin for the treatment of subnormal bone mineral density |
| 05/17/2006 | EP1214598B1 Screening for inhibitors of "paired helical filaments" |
| 05/17/2006 | EP1214409B1 Fibroblast growth factor-19 (fgf-19) nucleic acids and polypeptides and methods of use for the treatment of obesity |
| 05/17/2006 | EP1197221B1 G-csf preparations stabilized over long time |
| 05/17/2006 | EP1135515B1 Use of trans-activation and cis-activation to modulate the persistence of expression of a transgene |
| 05/17/2006 | EP1135411B1 Methods and compositions for treating disorders involving excitotoxicity |
| 05/17/2006 | EP1115372B1 Fast dissolving orally consumable films |
| 05/17/2006 | EP1113818B1 METHODS OF TREATING IgE-ASSOCIATED DISORDERS AND COMPOSITIONS FOR USE THEREIN |
| 05/17/2006 | EP1109914B1 Heme oxygenase 1 for the inhibition of smooth muscle cell migration |
| 05/17/2006 | EP1094849B1 Methods for increasing vascularization and promoting wound healing |
| 05/17/2006 | EP1071712B1 Sp22, a fertility-associated protein from sperm and a method for evaluating and affecting male fertility using it |
| 05/17/2006 | EP1067183B1 Novel g protein-coupled receptor proteins |
| 05/17/2006 | EP1048727B1 Gene encoding novel transmembrane protein |
| 05/17/2006 | EP1035866B1 Mixed lipopeptide micelles for inducing an immune response and their therapeutic uses |
| 05/17/2006 | EP1007729A4 COMPLEX FORMATION BETWEEN dsDNA AND OLIGOMER OF HETEROCYCLES |
| 05/17/2006 | EP0975668B1 MODIFIED TNFalpha MOLECULES, DNA ENCODING SUCH MODIFIED TNFalpha MOLECULES AND VACCINES COMPRISING SUCH MODIFIED TNFalpha MOLECULES AND DNA |
| 05/17/2006 | EP0973391B1 Endoderm, cardiac and neural inducing factors |
| 05/17/2006 | EP0938900B1 Preventives/remedies for stomatitis |
| 05/17/2006 | EP0923941B1 Remedies for myeloma to be used together with nitrogen mustard antitumor agents |
| 05/17/2006 | EP0904410B1 Identification of pyrazinamide-resistant mycobacteria and methods for treating mycobacterial infections |
| 05/17/2006 | EP0894136B1 Method of treating muscular disorders |
| 05/17/2006 | EP0807124B1 Monoclonal antibody against flt4 receptor tyrosine kinase and its use in diagnosis and therapy |
| 05/17/2006 | EP0796273B1 Variants of human papilloma virus antigens |
| 05/17/2006 | EP0777490B1 Mutant enterotoxin effective as a non-toxic oral adjuvant |
| 05/17/2006 | EP0716610B1 Human bone morphogenetic proteins for use in neural regeneration |
| 05/17/2006 | CN1774449A Inhibitors of MEMAPSIN2 and use thereof |
| 05/17/2006 | CN1774448A Growth factor complexes and modulation of cell migration and growth |
| 05/17/2006 | CN1774446A Identification of N-alkylglycine trimers for induction of apoptosis |
| 05/17/2006 | CN1774281A Pharmaceutical composition comprising proteins and/or polypeptides and colloidal particles |